

April 13, 2005

Suzuken Co., Ltd.

Yoshiki Bessho, President and CEO

Stock Code: 9987

Securities Traded: Tokyo, Nagoya, and Sapporo Stock Exchanges

Contact: Masami Kamiya, Managing Executive Officer

General Manager, Corporate Planning Headquarters

Tel: 052-961-2331

Suzuken Co., Ltd. Amends Projected Financial Results for the Fiscal Year Ended March 31, 2005

Suzuken Co., Ltd. has amended its projected financial results for the fiscal year ended March 31, 2005, which were announced on November 15, 2004. The amended projected financial results are detailed below.

1. Amended projected non-consolidated financial results for the fiscal year ended March 31, 2005 (millions of yen)

	Net Sales	Ordinary Income	Net Income
Before amendment (A)	1,206,000	13,200	7,000
After amendment (B)	1,231,600	16,400	8,900
Difference (B) - (A)	25,600	3,200	1,900
Percentage change (%)	2.1	24.2	27.1
Previous fiscal year ended March 31, 2004	1,124,081	24,709	14,572

2. Amended projected consolidated financial results for the fiscal year ended March 31, 2005 (millions of yen)

	Net Sales	Ordinary Income	Net Income
Before amendment (A)	1,327,000	18,900	10,000
After amendment (B)	1,330,000	21,800	11,900
Difference (B) - (A)	3,000	2,900	1,900
Percentage change (%)	0.2	15.3	19.0
Previous fiscal year ended March 31, 2004	1,194,024	29,492	17,307

3. Reasons

The ethical pharmaceutical market during the fiscal year that ended in March 2005 was characterized by extremely difficult price negotiations. Reductions in drug reimbursement prices by Japan's national health insurance system prompted medical institutions to make even greater demands for discounts. Exerting additional pressure on prices was intensifying competition among pharmaceutical wholesalers as medical institutions concentrated procurement activities on fewer suppliers. However, this pressure on prices eased somewhat during the fiscal year's fourth quarter.

In response to these challenges, Suzuken placed priority on actions aimed at improving its gross profit margin during the fiscal year's second half. As a result, the gross profit margin for the fiscal year did not decline as much as had been forecast.

The non-consolidated net sales forecast reflects higher sales associated with ASTIS Co., Ltd., which became a Suzuken subsidiary in October 2004.